Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug ...

LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...

The NDA submission for the treatment of presbyopia is supported by the positive data results from the pivotal Phase 3 CLARITY study. Aceclidine is a new chemical entity in the United States and is not ...

LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, ...

Leerink Partnrs lifted their FY2028 EPS estimates for LENZ Therapeutics in a research report issued on Tuesday, October 15th.

LENZ Therapeutics CEO Eef Schimmelpennink discusses how the company’s incredible innovation will change the status quo—especially for people over the age of 45. Pick the right team.

She most recently served as President and CEO of Graphite Bio, which she successfully merged with LENZ Therapeutics (Nasdaq: LENZ). “As we advance our development candidates for Rett syndrome ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Friday, Neumora Therapeutics Inc (NMRA) stock saw a decline, ending the day at $16.49 which represents a decrease of $-0.47 or -2.77% from the prior close of $16.96. The stock opened at $17 and ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $15.51, but opened at ...

In terms of valuation, Neumora Therapeutics Inc’s market capitalization stands at $2.71 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...